Progenra has a portfolio of novel first in class small molecules in addition to a novel PROTAC platform. We use an exclusive research platform to identify novel therapeutic medicines based on the ubiquitin proteasome system. We seek to add value to pharmaceutical and biotechnology company ventures and to create new programs with interested parties. Progenra invites partnership, funding and investment opportunities from both small and large institutions. Our unsurpassed know-how, diverse chemical library, and portfolio of novel first in class NCEs are paving the way for a new class of drug.
Progenra’s Financial Conflict of Interest Policy